Year Founded
2012
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Small molecule

Riboscience General Information

Phase 1 trial of RBS2418 (ENPP1 inhibitor) shows safety and efficacy in advanced solid tumors. 60% of ENPP1/cGAS-positive patients achieved stable disease. No DLTs or treatment-related SAEs observed.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Sunnyvale, California
United States

Drug Pipeline

RBS2418
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Riboscience's pipeline data

Book a demo

Key Partnerships

AstraZeneca, Sanofi, UC San Francisco

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Riboscience Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Riboscience's complete valuation and funding history, request access »